SG11201801873TA - Process and compositions for achieving mammalian energy balance - Google Patents

Process and compositions for achieving mammalian energy balance

Info

Publication number
SG11201801873TA
SG11201801873TA SG11201801873TA SG11201801873TA SG11201801873TA SG 11201801873T A SG11201801873T A SG 11201801873TA SG 11201801873T A SG11201801873T A SG 11201801873TA SG 11201801873T A SG11201801873T A SG 11201801873TA SG 11201801873T A SG11201801873T A SG 11201801873TA
Authority
SG
Singapore
Prior art keywords
compositions
energy balance
mammalian energy
achieving
achieving mammalian
Prior art date
Application number
SG11201801873TA
Inventor
Muhammed Majeed
Anjali Pandey
Kalyanam Nagabhushanam
Sarang Bani
Original Assignee
Sami Labs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Labs Ltd filed Critical Sami Labs Ltd
Publication of SG11201801873TA publication Critical patent/SG11201801873TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
SG11201801873TA 2015-11-10 2015-11-11 Process and compositions for achieving mammalian energy balance SG11201801873TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/936,830 US10085963B2 (en) 2015-11-10 2015-11-10 Process and compositions for achieving mammalian energy balance
PCT/US2015/060176 WO2017082896A1 (en) 2015-11-10 2015-11-11 Process and compositions for achieving mammalian energy balance

Publications (1)

Publication Number Publication Date
SG11201801873TA true SG11201801873TA (en) 2018-05-30

Family

ID=58668245

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201801873TA SG11201801873TA (en) 2015-11-10 2015-11-11 Process and compositions for achieving mammalian energy balance

Country Status (12)

Country Link
US (1) US10085963B2 (en)
EP (1) EP3194575B1 (en)
JP (1) JP6472453B2 (en)
KR (1) KR102169620B1 (en)
CN (1) CN108138141B (en)
AU (1) AU2015351423B2 (en)
EA (1) EA038685B1 (en)
MX (1) MX2018004735A (en)
MY (1) MY188869A (en)
PL (1) PL3194575T3 (en)
SG (1) SG11201801873TA (en)
WO (1) WO2017082896A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3695676B1 (en) 2017-10-11 2022-04-06 Telefonaktiebolaget LM Ericsson (publ) Uci on grant-free pusch
KR20230119160A (en) * 2020-12-17 2023-08-16 새미-사빈사 그룹 리미티드 Compositions targeting advanced glycation end product receptor (RAGE) in chronic inflammatory conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06133731A (en) * 1992-10-23 1994-05-17 Zenetsukusu Kk Diet food
US6153432A (en) * 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
JP4432069B2 (en) * 2002-09-03 2010-03-17 ビーエイチエヌ株式会社 Obesity inhibitor
US20090098220A1 (en) * 2007-10-12 2009-04-16 Lance Ashworth Liquid pharmaceutical preparation comprising forskolin for promoting lean body mass
FR2960549B1 (en) * 2010-05-25 2015-06-19 Univ Paris Curie PROCESS FOR CULTIVATION OF ADIPOCYTES
WO2013109241A1 (en) * 2011-01-10 2013-07-25 Muhammed Majeed Anti-obesity potential of calebin a
MX2014009308A (en) * 2012-02-29 2014-10-14 Avon Prod Inc Use of cpt-1 modulators and compositions thereof.
SG10201607521PA (en) * 2012-03-12 2016-10-28 Univ Singapore Generation of brown adipose tissue (bat) from mesenchymal cells
WO2013188138A1 (en) * 2012-06-11 2013-12-19 The Regents Of The University Of California Inhibitors of hippo-yap signaling pathway
US20150216935A1 (en) * 2012-08-09 2015-08-06 Brown University Autologous Cell-Based Therapy for Treating Obesity
CA2883253C (en) * 2012-08-31 2019-09-03 Halliburton Energy Services, Inc. System and method for measuring gaps using an opto-analytical device
US20170014455A1 (en) * 2014-03-13 2017-01-19 The J. David Gladstone Instiutes, a testamentary trust established under the Will of J. David Glads Inducing brown fat fate and function

Also Published As

Publication number Publication date
AU2015351423A1 (en) 2017-05-25
EP3194575B1 (en) 2020-04-29
AU2015351423A2 (en) 2017-08-24
JP2018508179A (en) 2018-03-29
MY188869A (en) 2022-01-11
KR20180057718A (en) 2018-05-30
WO2017082896A1 (en) 2017-05-18
KR102169620B1 (en) 2020-10-23
AU2015351423B2 (en) 2018-08-09
EA038685B1 (en) 2021-10-05
CN108138141A (en) 2018-06-08
US10085963B2 (en) 2018-10-02
PL3194575T3 (en) 2020-11-02
EP3194575A4 (en) 2017-12-27
EP3194575A1 (en) 2017-07-26
MX2018004735A (en) 2018-07-06
CN108138141B (en) 2021-12-03
NZ720422A (en) 2019-08-30
US20170128410A1 (en) 2017-05-11
JP6472453B2 (en) 2019-02-20
EA201791155A1 (en) 2017-09-29

Similar Documents

Publication Publication Date Title
HK1247245A1 (en) Methods and compositions for inducing hematopoietic cell differentiation
HK1257295A1 (en) Compositions and methods for immunooncology
HK1243333A1 (en) Methods and compositions for modified t cells
SG11201803145RA (en) Methods and compositions for inducing hematopoietic cell differentiation
IL251576A0 (en) Methods and compositions for generating or maintaining pluripotent cells
IL264454A (en) Novel compositions, uses and methods for making them
EP3383411A4 (en) Methods and compositions relating to chondrisomes from cultured cells
HK1259277A1 (en) Structural composition and method
EP3331582A4 (en) Methods and compositions for treating cells for transplant
PL3394248T3 (en) Dendritic cell composition
HK1246193A1 (en) Methods and compositions for improved cognition
HK1245158A1 (en) Apilimod compositions and methods for using same
HK1247927A1 (en) Novel compositions, uses and methods for making them
PT3250550T (en) Compositions and methods for viral sensitization
GB2550632B (en) Compositions and uses and methods relating thereto
GB201502983D0 (en) Composition and process
SG11201801873TA (en) Process and compositions for achieving mammalian energy balance
EP3397071C0 (en) Composition for energy supplementation
PT3394248T (en) Dendritic cell composition
GB201617498D0 (en) Energy balance
GB201507667D0 (en) Composition & process